'Some Hope Is Better Than Having No Hope'

Roughly a year ago, a team at The New York Times Magazine set about tackling a nearly impossible task: creating a list of the greatest living American songwriters. But how to take the tens of thousands of songwriters working in this country and narrow them down to a digestible li ...  Show more

The conservative media commentator split with the administration over the war in Iran. Will the breakup last? Thoughts? Email us at theinterview@nytimes.com Watch our show on YouTube: youtube.com/@TheInterviewPodcast For transcripts and more, visit: nytimes.com/theinterview Subsc ...  Show more

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ...  Show more

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ...  Show more

Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ...  Show more

An overwhelming demand for ADHD diagnoses has left the NHS struggling to keep up. What’s behind the rise?

Content warning: This episode contains mentions of suicidal thoughts and eating disorders.

This podcast was brought to you thanks to the s ...